Andra AP fonden Lowers Stake in IDEXX Laboratories, Inc. $IDXX

Andra AP fonden lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 73.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,723 shares of the company’s stock after selling 13,077 shares during the period. Andra AP fonden’s holdings in IDEXX Laboratories were worth $2,533,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at $29,000. Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $36,000. NewSquare Capital LLC grew its position in shares of IDEXX Laboratories by 87.5% in the second quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after purchasing an additional 35 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after purchasing an additional 30 shares during the period. Finally, WPG Advisers LLC acquired a new position in IDEXX Laboratories in the first quarter valued at $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the transaction, the executive vice president owned 11,287 shares in the company, valued at $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the completion of the sale, the executive vice president directly owned 16,807 shares of the company’s stock, valued at $11,034,299.71. The trade was a 6.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,793 shares of company stock valued at $2,467,430 over the last three months. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

IDXX opened at $708.45 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $735.00. The company has a 50 day moving average of $645.28 and a two-hundred day moving average of $578.23. The company has a market cap of $56.68 billion, a P/E ratio of 58.99, a P/E/G ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 3rd. The company reported $3.40 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.26. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $2.80 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the topic of a number of research analyst reports. Morgan Stanley raised their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research report on Monday. Jefferies Financial Group restated a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $730.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.